

CTAD

2025

Clinical Trials on Alzheimer's Disease

PRELIMINARY PROGRAM

December 1-4, 2025

San Diego, CA, USA

Montpellier '08 • Las Vegas '09 • Toulouse '10 • San Diego '11 • Monte Carlo '12 • San Diego '13
Philadelphia '14 • Barcelona '15 • San Diego '16 • Boston '17 • Barcelona '18 • San Diego '19
Virtual '20 • Boston '21 • San Francisco '22 • Boston '23 • Barcelona '24

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

JPAD
THE JOURNAL
OF PREVENTION
OF ALZHEIMER'S
DISEASE



MONDAY, DECEMBER 1

3:45 pm 4:20 pm	<p>Welcome ceremony and CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research presented to <u>Takeshi Iwatsubo</u> MD, PhD in recognition for his pioneering work in Alzheimer's Disease neuroimaging and neuropathology</p> <p>Introduction by the CTAD Organizing Committee</p>
4:20 pm 4:45 pm	<p>KEYNOTE 1: " ENHANCING PARTICIPATION OF REPRESENTATIVE POPULATIONS IN ALZHEIMER DISEASE CLINICAL TRIALS"</p> <p><u>Sid O'Bryant</u>, PhD, <i>Principal Investigator of the Health & Aging Brain Study, The University of North Texas Health Science Center at Fort Worth – Fort Worth, TX (United States)</i></p>
4:45 pm 6:15 pm	<p>LATE BREAKING COMMUNICATIONS</p>
6:15 pm 6:55 pm	<p>SYMPOSIUM 1: Trontinemab's path to Phase III – From proof-of-concept in the ongoing Brainshuttle™ AD study to the pivotal studies TRONTIER 1 and TRONTIER 2 in people with early-stage symptomatic Alzheimer's disease</p> <p><i>Chair: Wiesje van der Flier, Alzheimer Center Amsterdam, Amsterdam (The Netherlands)</i></p> <p>Presentation 1: Brainshuttle™ AD: New interim results of a randomized, placebo-controlled Phase Ib/IIa proof-of-concept study with trontinemab, a novel anti-amyloid monoclonal bispecific antibody for the treatment of Alzheimer's disease</p> <p><i>Luka Kulic, F. Hoffmann-La Roche Ltd - Basel (Switzerland)</i></p> <p>Presentation 2: TRONTIER 1 and 2: Rationale and design of two identical Phase III trials to assess the efficacy and safety of trontinemab in early symptomatic Alzheimer's disease</p> <p><i>Catherine Mummery, Queen Square Institute of Neurology, UCL – London (United Kingdom)</i></p> <p>Presentation 3: The TRAVELLER master pre-screener protocol: An approach to reduce participant burden and broaden access to clinical trials in Alzheimer's disease</p> <p><i>Christopher Lane, Roche Products Ltd - Welwyn Garden City (United Kingdom)</i></p>
7:00 pm 8:00 pm	<p>CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association</p>

TUESDAY, DECEMBER 2

7:30 am

8:30 am

POSTER WALKING TOUR

8:30 am

9:15 am

LATE BREAKING COMMUNICATIONS

9:15 am

9:40 am

KEYNOTE 2: FROM REAL WORLD DATA TO CLINICAL TRIALS: THE CASE FOR SEMAGLUTIDE IN ALZHEIMER'S DISEASE

Peter Johannsen, MD, PhD, International Medical Vice President, Novo Nordisk, Copenhagen (Denmark)

9:40 am

10:40 am

ORAL COMMUNICATIONS

OC1: The effect of herpes zoster vaccination at different stages of the dementia disease course: Implications for defining the study population of clinical trials

Min Xie¹, Markus Eyting¹, Christian Bommer¹, Haroon Ahmed², Pascal Geldsetzer¹

¹Stanford University - Stanford (United States), ²Cardiff University - Cardiff (United Kingdom)

OC2: CSF MTBR-tau243 improves prediction of longitudinal clinical progression and trial efficiency in early Alzheimer's disease

Viswanath Devanarayan¹, Todd Nelson¹, Thomas Doherty², Erica Andreozzi¹, Kristin Wildsmith¹, Pallavi Sachdev¹, Kanta Horie¹, Arnaud Charil¹, Harald Hampel¹, Lynn Kramer¹, Shobha Dhadha¹, Michael Irizarry¹

¹Eisai Inc. - Nutley (United States), ²Eisai Inc. - Hatfield (United Kingdom)

OC3: Biological staging of Alzheimer's disease using blood-based biomarkers

Gemma Salvadó^{1,2}, Kanta Horie^{3,4,5}, Nicholas Barthélemy^{3,4}, Suzanne E Schindler^{4,6}, Shorena Janelidze¹, Anna Orduña Dolado¹, Divya Bali¹, Erik Stomrud^{1,7}, Niklas Mattsson-Carlsson^{1,8,9}, Sebastian Palmqvist^{1,7}, Jacob W Vogel¹⁰, Randall J Bateman^{3,4,6,11}, Rik Ossenkoppele^{1,12,13}, Oskar Hansson¹

¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, - Lund (Sweden), ²Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ³The Tracy Family SILQ Center, Washington University School of Medicine - St Louis (United States), ⁴Department of Neurology, Washington University School of Medicine - St Louis (United States), ⁵Eisai Inc. - Nutley (United States), ⁶Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), ⁷Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁸Wallenberg Center for Molecular Medicine, Lund University - Lund (Sweden), ⁹Department of Neurology, Skåne University Hospital - Lund (Sweden), ¹⁰Department of Clinical Sciences Malmö, SciLifeLab, Lund University - Lund (Sweden), ¹¹Hope Center for Neurological Disorders, Washington University School of Medicine - St Louis (United States), ¹²Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), ¹³Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands)

OC4: The SMART-HS Study: A Targeted Therapeutic Strategy for LATE Disease

E. Pinar Coskun¹, Ahmed Bahrani¹, Lauren Bojarski¹, Justin Barber¹, Danica Coy¹, Emily Smith¹, Molly Harper¹, Alexandra Curtis¹, Erin Abner¹, Brian Gold¹, Linda Van Eldik¹, Peter Nelson¹, Gregory Jicha¹

¹University of Kentucky - Lexington (United States)

10:40 am

11:10 am

COFFEE BREAK AND POSTER SESSION

11:10 am

11:50 am

SYMPOSIUM 2: The U.S. POINTER Trial: Imaging, neurovascular, and sleep outcomes

Chair: Susan Landau, UC Berkeley - Berkeley (United States)

Presentation 1: U.S. POINTER Trial Outcomes: Results of the Imaging Ancillary Study

Susan Landau, UC Berkeley - Berkeley (United States)

Presentation 2: POINTER-NV: Results of the U.S. POINTER Neurovascular Ancillary Study

Tina E. Brinkley, Wake Forest University School of Medicine - Winston-Salem (United States)

Presentation 3: POINTER-zzz: Results of the U.S. POINTER Sleep Ancillary Study

Laura D. Baker, Wake Forest University School of Medicine - Winston-Salem (United States)

11:50 am

12:50 pm

LATE BREAKING COMMUNICATIONS

12:50 pm

1:30 pm

LUNCH ON YOUR OWN

1:30 pm

1:50 pm

COFFEE BREAK IN THE POSTER HALL

1:50 pm

3:20 pm

ORAL COMMUNICATIONS

OC5: The Effects of Lecanemab Treatment on Soluble CSF A β Protofibrils in Clarity AD

Kanta Horie¹, Akihiko Koyama¹, Pallavi Sachdev¹, Kazuyoshi Shuta², Kazuhiro Tahara², Michio Kanekiyo¹, Shobha Dhadda¹, Larisa Reyderman¹, Steven Hersch¹, Michael Irizarry¹, Lynn Kramer¹

¹Eisai Inc. - Nutley (United States), ²Eisai Co., Ltd. - Tsukuba (Japan)

OC6: Impact of a 10-Year Multidomain Lifestyle Intervention on Long-Term Risks for Cognitive Impairment: The Look AHEAD Program

Oral communications

Mark Espeland¹, Rebecca Neiberg¹, Haiying Chen¹, Stephen Rapp¹, Bonnie Sachs¹, Chinedu Udeh-Momoh¹, Laura Baker¹, Kathleen Hayden¹, Denise Houston¹, Jose Luchsinger², Rena Wing³, Sevil Yasar⁴, Lynne Wagenknecht¹

¹Wake Forest University School of Medicine - Winston Salem (United States),
²Columbia University Irving Medical Center - New York (United States), ³The Miriam Hospital - Providence (United States), ⁴Johns Hopkins School of Medicine - Baltimore (United States)

OC7: Outcomes from the BetterBrains Trial, a multi-domain, person-centred, dementia risk factor management randomised controlled trial to prevent cognitive decline

Emily Rosenich¹, Darshini Ayton¹, Stephanie Pirotta¹, Hannah Cummins¹, Maya Norfolk¹, Nawaf Yassi², Shantha Rajaratnam¹, Richard Sinnott², Matthew Pase¹, Amy Brodtmann¹, Ashley Bush³, Leonid Churilov², Anna Barker¹, Paul Maruff⁴, Yen Ying Lim¹

¹Monash University - Melbourne (Australia), ²University of Melbourne - Melbourne (Australia), ³Florey Institute - Melbourne (Australia), ⁴Cogstate Ltd - Melbourne (Australia)

OC8: Quantifying tau knockdown in individuals with Alzheimer's Disease receiving intrathecal tau MAPT antisense oligonucleotide NIO752 using Stable Isotope Labelling Kinetics (SILK) – interim analysis of a phase 1B randomised, double-blinded, placebo-controlled, multicentre trial

Aram Aslanyan^{1,2}, Chihiro Sato^{3,4}, Donald Elbert⁵, Catherine Mummery^{1,2}, Nupur Ghoshal³, Eric Mcdade³, Randall Bateman^{3,4,6}, Ross Paterson^{1,2,4,7}

¹Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London - London (United Kingdom), ²National Hospital for Neurology and Neurosurgery - London (United Kingdom), ³Department of Neurology, Washington University School of Medicine in St Louis - St. Louis (United States), ⁴The Tracy Family Stable Isotope Labeling Quantitation Center, Washington University School of Medicine, Washington University in St. Louis - St. Louis (United States), ⁵Department of Neurology, University of Washington - Seattle (United States), ⁶Dominantly Inherited Alzheimer Network, Washington University in St. Louis - St. Louis (United States), ⁷Darent Valley Hospital - Dartford (United Kingdom)

OC9: Insights into Clinical Trial Recruitment: An Analysis of Prescreening Data from the AHEAD Study

Dylan Kirn^{1,2}, Shunran Wang³, Karin Ernststrom³, Joshua D. Grill^{4,5}, Gustavo Jimenez-Maggiora³, Doris Molina-Henry³, Paul Aisen³, Reisa Sperling^{1,2}, Rema Raman³

¹Department of Neurology, Brigham and Women's Hospital - Boston (United States), ²Department of Neurology, Massachusetts General Hospital - Boston (United States), ³Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ⁴Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), ⁵Department of Psychiatry and Human Behavior, University of California Irvine - Irvine (United States)

OC10: Results from the open-label extension period of TOGETHER, a Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild Alzheimer's disease

William Byrnes¹, Irene Rebollo Mesa², Tim Buchanan³, Bart Van Den Steen³, Hans Van Tricht³, Katie Taiyari⁴, Omobola Famodimu⁵, Jos Bloemers⁶, Saori Shimizu⁷, Ute Massow⁸, Ralph P. Maguire³, Colin Ewen⁴

¹UCB - Raleigh (United States), ²UCB - Madrid (Spain), ³UCB - Braine-L'alleud (Belgium), ⁴UCB - Slough (United Kingdom), ⁵UCB - Oakville (Canada), ⁶UCB - Breda (Netherlands), ⁷UCB - Brussels (Belgium), ⁸UCB - Monheim Am Rhein (Germany)

3:20 pm

4:00 pm

ROUNDTABLE 1: Charting the Path Forward for Combination Therapy in Alzheimer's Disease: Challenges, Considerations, and Collaborative Solutions

Chair: Howard Fillit, *Alzheimer's Drug Discovery Foundation, New York City (United States)*

Presentation 1: Add-On Combination Therapy with Monoclonal Antibodies: Implications for Drug Development

Jeffrey Cummings, *Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, UNLV - Las Vegas, (United States)*

Presentation 2: Considerations in the Development and Use of Biomarkers for Combination Therapy in Alzheimer's Disease

Suzanne Schindler, *Knight Alzheimer's Disease Research Center, Washington University School of Medicine – St. Louis (United States)*

Presentation 3– Regulatory Perspective on Future Combination Trials

Billy Dunn, *Prothena Biosciences Inc, Brisbane (United States)*

Discussion: Jeffrey Cummings (Moderator)¹, Suzanne Schindler², Billy Dunn³, Howard Fillit⁴, Szofia Bullain⁵

¹*Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada at Las Vegas, Las Vegas, NV, USA;* ²*Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA;* ³*Prothena Biosciences Inc, Brisbane, CA, USA;* ⁴*Alzheimer's Drug Discovery Foundation, New York, NY, USA;* ⁵*Biogen, Cambridge, MA, USA.*

4:00 pm

4:30 pm

4:30 pm

5:30 pm

COFFEE BREAK AND POSTER SESSION

LATE BREAKING COMMUNICATIONS

WEDNESDAY, DECEMBER 3

7:30 am POSTER WALKING TOUR
8:30 am

PROGRAM PLENARY ROOM

8:30 am LATE BREAKING COMMUNICATION
9:30 am

9:30 am **Keynote 3: Next Generation Anti-Amyloid TherapiesShuttling Past**
9:55 am **the ARIA Risk**

Ronald B. DeMattos, PhD, Senior Vice President and Chief Scientific Officer for Neurobiologics, Eli Lilly and Company – Indianapolis, IN (United States)

9:55 am ORAL COMMUNICATIONS
10:55 am

OC11: Combining endogenous CSF MTBR-tau243 and plasma pTau217 enhances prediction of continuous regional tau PET burden in amyloid-positive early Alzheimer's disease

Viswanath Devanarayan¹, Thomas Doherty², Erica Andreozzi¹, Kristin Wildsmith¹, Pallavi Sachdev¹, Kanta Horie¹, Arnaud Charil¹, Harald Hampel¹, Lynn Kramer¹, Shobha Dhadda¹, Michael Irizarry¹

¹Eisai Inc. - Nutley (United States), ²Eisai Inc. - Hatfield (United Kingdom)

OC12: Brain volume changes with gantenerumab: relationship with amyloid removal

Matteo Tonietto¹, Erica Silvestri^{1,2}, Christopher Belder^{3,4}, Frederik Barkhof^{3,5}, Nick Fox³, Janice Smith⁶, Gregory Klein¹

¹Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²A4P Consulting Ltd - Sandwich (United Kingdom), ³Dementia Research Centre, UCL Queen Square Institute of Neurology - London (United Kingdom), ⁴Department of Neurology, Royal Adelaide Hospital and Queen Elizabeth Hospital - Adelaide (Australia), ⁵Department of Radiology & Nuclear Medicine - Amsterdam (Netherlands), ⁶Roche Products Ltd - Welwyn Garden City (United Kingdom)

OC13: Head-to-head comparison of SWI and T2*-weighted gradient echo MRI sequences to detect ARIA-H in the TRAILBLAZER-ALZ 6 trial of donanemab

Diana Svaldi¹, Alessandro Biffi¹, Hong Wang¹, Emel Serap Nery¹, Chuning Gao¹, Ming Lu¹, Emily Collins¹, Karolina Feakins¹, Sergey Shcherbinin¹, Dawn Brooks¹, John Sims¹

¹Eli Lilly and Company - Indianapolis (United States)

OC14: Longitudinal trajectories of plasma p-tau217 in cognitively unimpaired older adults using a fully automated platform

Marisa N. Denking¹, Sterling C. Johnson², Alpana Singh¹, Taina Marques¹, Rachael E. Wilson², Ramiro E. Rea Ryes², Antoine Leuzy¹, Valentina Ghisays³, Robert C. Alexander³, Reisa A. Sperling⁴, Keith A.

Johnson⁵, Paul A. Aisen⁶, Jessica B. Langbaum³, Eric M. Reiman³, Nicholas J. Ashton³

¹Banner Sun Health Research Institute - Sun City (United States), ²Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison - Madison (United States),

³Banner Alzheimer's Institute - Phoenix (United States), ⁴Department of Neurology, Massachusetts General Hospital, Harvard Medical School, - Boston (United States), ⁵Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital - Boston (United States), ⁶Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

10:55 am

11:25 am

11:25 am

12:35 pm

COFFEE BREAK AND POSTER SESSION

Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease

Introduction by Chair: Howard Fillit, Alzheimer's Drug Discovery Foundation, New York, NY (United States)

OC15: Protein-based Diagnosis and Analysis of Co-pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma Proteomic Classifier

Ying Xu^{1,2}, Daniel Western^{1,2}, Gyujin Heo^{1,2}, Kwangsik Nho³, Hamilton Oh⁴, Yike Chen^{1,2}, Menghan Liu^{1,2}, Katherine Gong¹, Agustin Ruiz^{5,2}, Maria Victoria Fernández^{6,1}, David Bennett^{7,6,8}, Tony Wyss-Coray⁹, Muhammad Ali^{1,2}, Carlos Cruchaga^{1,2}

¹Department of Psychiatry, Washington University School of Medicine - St Louis (United States), ²NeuroGenomics and Informatics Center, Washington University School of Medicine - St Louis (United States), ³Indiana University School of Medicine - Indianapolis (United States), ⁴Icahn School of Medicine at Mount Sinai - New York (United States), ⁵Ace Alzheimer Center Barcelona - Barcelona (Spain), ⁶CIBERNED, National Institute of Health Carlos III - Madrid (Spain), ⁷Rush Alzheimer's Disease Center, Rush University Medical Center - Chicago (United States), ⁸Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, - San Antonio (United States), ⁹Wu Tsai Neurosciences Institute, Stanford University - California (United States)

OC16: Identifying and stratifying Alzheimer's disease using circular RNA biomarkers in blood

Bridget Phillips^{1,2,3}, Jessie Sanford^{1,2,3}, Devin Dikec^{1,2,3}, Menghan Liu^{1,2,3}, Matt Johnson^{1,2,3}, John Budde^{1,2,3}, John Morris^{4,5,6}, Nikolaos Mellios⁷, Alison Goate⁸, Alan Renton⁸, Dominantly Inherited Alzheimer Network Consortia⁹, Richard Perrin^{4,5,6}, Laura Ibanez^{1,2,4}, Carlos Cruchaga^{2,1,3}

¹Department of Psychiatry, Washington University School of Medicine - St. Louis (United States), ²NeuroGenomics and Informatics Center, Washington University School of Medicine - St. Louis (United States), ³Hope Center for Neurological Disorders, Washington University School of Medicine - St. Louis (United States), ⁴Department of Neurology, Washington University School of Medicine - St. Louis (United States), ⁵Department of Pathology and Immunology, Washington University School of Medicine - St. Louis (United States), ⁶Knight Alzheimer Disease Research Center, Washington University School of Medicine - St. Louis (United States), ⁷Circular Genomics Inc - San Diego (United States), ⁸Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai - New York (United States), ⁹Dominantly Inherited Alzheimer Network (DIAN) - St. Louis (United States)

OC17: Large-scale Plasma Proteomic Profiling Unveils Diagnostic Biomarkers and Pathways for Alzheimer's Disease

Gyujin Heo¹, Xu Ying¹, Timsina Jigyasha¹, Western Daniel¹, Cruchaga Carlos¹

¹Washington University - Saint Louis (United States)

OC18: Biomarkers Associated with Response to Treatment of Early Stage AD with Pepinemab, Anti-SEMA4D Blocking Antibody

Maurice Zauderer¹, Elizabeth Evans¹, Terrence Fisher¹, Vikas Mishra¹, Leslie Balch¹, Elaine Gersz¹, John Leonard¹, Crystal Mallow¹, Anton Porsteinsson², Raymond Turner³, John Huffaker⁴

¹Vaccinex, Inc. - Rochester (United States), ²University of Rochester - Rochester (United States), ³Georgetown University - Washington, Dc (United States), ⁴Neuropsychiatric Research Center - Southwest Florida (United States)

12:35 pm

1:15pm

1:15 pm

1:30 pm

LUNCH ON YOUR OWN

COFFEE BREAK IN THE POSTER HALL

1:30 pm

2:10 pm

SYMPOSIUM 3: ALZNET: First Look at Real-World Use of Novel Alzheimer's Disease Therapies in the United States

Chair: Reisa Sperling, *Brigham and Women's Hospital - Massachusetts General Hospital - Boston (United States)*

Presentation 1: ALZNET: An Update on Registry Growth and Collaborations

Maria C Carrillo, *Alzheimer's Association - Chicago (United States)* on behalf of the ALZ-NET Study Team

Presentation 2: The ALZ-NET patient population: Demographics, Genetics and Biomarker Testing

Gil D Rabinovici, Memory and Aging Center, UCSFR – San Francisco (United States) on behalf of the ALZ-NET Study Team

Presentation 3: Longitudinal assessment of clinical and safety outcomes in participants receiving beta-amyloid targeting monoclonal antibodies: Real world therapy data from ALZ-NET

Michael S Rafii, *USC-ATRI, San Diego (United States)* on behalf of the ALZ-NET Study Team

2:10 pm

3:55 pm

3:55 pm

4:25 pm

4:25 pm

5:10 pm

LATE BREAKING COMMUNICATIONS

COFFEE BREAK AND POSTER SESSION

ORAL COMMUNICATIONS

OC19: Alpha-Synuclein Detection: A Versatile EV-Based Plasma Assay for Detecting Modified α -Synuclein in Synucleinopathies Without Pre-Enrichment

Carine Lim¹, Hui Ling Ko¹, Brian Minie¹, Nicole Tsang¹, Nicholas Ho¹, Huilin Shao¹, Richard Batrla²

¹Sunbird Bio - Singapore (Singapore), ²Sunbird Bio - Cambridge (United States)

OC20: Population characteristics and implications of implementation strategies for blood-based biomarkers in Alzheimer's disease across

healthcare settings: Insights from a prospective, global, multicenter study

Imke Kirste¹, Sayuri Hortsch², Craig Ritchie^{3,4}, Jeffery L Dage^{5,6,7}, Kristian Steen Frederiksen^{8,9}, Marc Suárez-Calvet^{10,11,12}, Marwan N Sabbagh¹³, Clara Quijano-Rubio¹⁴

¹Roche Diagnostics Solutions - Indianapolis (United States), ²Roche Diagnostics GmbH - Penzburg (Germany), ³Scottish Brain Sciences - Edinburgh (United Kingdom), ⁴Department of Medicine, University of St Andrews - St Andrews (United Kingdom), ⁵Department of Neurology, Indiana University School of Medicine - Indianapolis (United States), ⁶Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine - Indianapolis (United States), ⁷Stark Neurosciences Research Institute, Indiana University School of Medicine - Indianapolis (United States), ⁸Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet - Copenhagen (Denmark), ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen - Copenhagen (Denmark), ¹⁰Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ¹¹Hospital del Mar Research Institute - Barcelona (Spain), ¹²Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ¹³Department of Neurology, Barrow Neurological Institute - Phoenix (United States), ¹⁴Roche Diagnostics International Ltd - Rotkreuz (Switzerland)

OC21: Donanemab in Early Symptomatic Alzheimer's Disease: Additional Insights from the TRAILBLAZER-ALZ 2 Long-Term Extension

John Sims¹

¹Eli Lilly and Company - Indianapolis (United States)

5:10 pm

5:50 pm

SYMPOSIUM 4: TOPLINE RESULTS from evoke and evoke+: two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease

Jeffrey L. Cummings¹, Alireza Atri^{2,3,4}, Howard H. Feldman⁵, Mary Sano^{6,7}, Wiesje Van Der Flier^{8,9}, Henrik Zetterberg¹⁰, Filip K. Knop¹¹, Peter Johannsen¹¹, Teresa León¹¹, Rikke Mortensen Abschneider¹¹, Philip Scheltens^{12,13}

¹Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas - Las Vegas (United States), ²Banner Sun Health Research Institute - Sun City (United States), ³Banner Alzheimer's Institute, - Phoenix (United States), ⁴Brigham and Women's Hospital, Harvard Medical School - Boston (United States), ⁵Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California San Diego - La Jolla (United States), ⁶Icahn School of Medicine at Mount Sinai - New York (United States), ⁷James J Peters, VAMC - Bronx (United States), ⁸Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ⁹Amsterdam Neuroscience, Neurodegeneration, - Amsterdam (Netherlands), ¹⁰Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden), ¹¹Novo Nordisk A/S - Copenhagen (Denmark), ¹²Alzheimer Center, Department of Neurology, Vrije Universiteit Amsterdam - Amsterdam Umc (Netherlands), ¹³EQT Life Sciences - Amsterdam (Netherlands)

THURSDAY, DECEMBER 4

7 :30 am
8 :30 am

POSTER WALKING TOUR

PROGRAM PLENARY ROOM

8 :30 am
9 :30 am

LATE BREAKING COMMUNICATIONS

9 :30 am
10 :40 am

AD CLINICAL TRIALS – ORAL COMMUNICATIONS - PHASE 1 SESSION

OC22: A first-in-human double-blind, placebo-controlled, multiple ascending dose phase 1 study evaluating the safety and pharmacokinetics of PRX005/BMS-986446, a novel anti-MTBR tau monoclonal antibody, in healthy adults and patients with Alzheimer's disease

David P. Walling¹, Ferenc Martenyi², Brian Campbell², Jun Lee², Philip Dolan², Donna Masterman², Chad Swanson², Mark Thomas³, Min Chen³, Aditi Shahane³, Nicholas Colletti³, Nanette Hock³, Ilena George³

¹CenExel - Los Alamitos (United States), ²Prothena - Brisbane (United States), ³Bristol Myers Squibb - Princeton (United States)

OC23: First-in-Human Study of ADEL-Y01, a Monoclonal Antibody Targeting Acetylated Tau (ack280) in the MTBR: Safety and Pharmacokinetics in Healthy Adults and Early Alzheimer's Disease

Min-Seok Kim^{1, 2}, Yuna Oh¹, Sungsil Lee³, Kyung-Hoon Hwang¹, Young-Soo Sohn¹, Dong-Sik Jung³, Taeyoung Yoon³, Peter J. Winkle⁴, Seung-Yong Yoon^{1, 2}

¹ADEL Institute of Science & Technology (AIST), ADEL, Inc. - Seoul (Korea, Republic of), ²Department of Brain Science, Asan Medical Center, University of Ulsan College of Medicine - Seoul (Korea, Republic of), ³Oscotec Inc. - Gyeonggi-Do (Korea, Republic of), ⁴CenExel ACT - Anaheim (United States)

OC24: Amyloid-related imaging abnormalities in an ongoing Phase 1 study of mivelsiran, an investigational RNA interference therapeutic targeting amyloid precursor protein, in patients with Alzheimer's disease

Neal S Parikh¹, Sharon Cohen², Sandeep Chaudhari¹, Lynn Farugia¹, Andrew H Ahn¹, Julia Shirvan¹, Steven M Greenberg³

¹Alnylam Pharmaceuticals, Inc. - Cambridge (United States), ²Toronto Memory Program/Toronto Memory Program - Toronto (Canada), ³Harvard Medical School, Massachusetts General Hospital - Boston (United States)

OC25: Results of a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of VY7523, a tau-targeting therapeutic, in healthy adult participants

Elena Ratti¹, Monroe Butler¹, Naomi Muse¹, Sarah Piantedosi¹, Thrusha Chauhan¹, Beth Mellen¹, Joydip Kundu¹, Vik Arora¹, Albenia Patroneva², Maurice Emery², Raj Rajagovindan¹, Toby Ferguson¹, Alfred Sandrock¹

¹Voyager Therapeutics - Lexington (United States), ²Voyager Therapeutics Contractor - Lexington (United States)

OC26: ABCA1-agonist treatment by CS6253 and effects on plasma total and isoform-specific apolipoprotein E in elderly men and women.

Jan Johansson¹, Bengt Winblad², Henrik Zetterberg³, Jeffrey Cummings⁴, Dobrin Nedelkov⁵, Hussein Yassine⁶

¹Artery Therapeutics, Inc. - San Ramon (United States), ²Karolinska - Stockholm (Sweden), ³Sahlgrenska - Gothenburg (Sweden), ⁴U of Nevada - Las Vegas (United States), ⁵Isoformix Inc. - Sugarland (United States), ⁶USC - Los Angeles (United States)

OC27: Efficacy and safety of xanomeline and trospium chloride for cognitive impairment in Alzheimer's disease (MINDSET-1 and MINDSET-2)

Jeffrey L Cummings¹, William P Horan^{2,3}, Dongmei Liu⁴, Jessica Stanek⁴, Codrin Lungu⁴

¹University of Nevada - Las Vegas (United States), ²University of California - Los Angeles (United States), ³Bristol Myers Squibb* - Princeton (United States), ⁴Bristol Myers Squibb - Princeton (United States)

OC28: SToMP and STAMINA Clinical Trials of Senolytics in Alzheimer's Disease Treatment and Prevention

Miranda E. Orr, Washington University in St Louis - St. Louis (United States)

OC29: Pleiotropic Effects of the CNS-Selective M1 Muscarinic Agonist NSC001: From Rapid Symptomatic Relief to Long-Term Disease Modification in Alzheimer's Disease (AD)

Manfred Windisch¹, Abraham Fisher²

¹NSC-Therapeutics GmbH - St. Radegund (Austria), ²ADPD - Holon (Israel)

10 :40 am

11 :10 am

COFFEE BREAK AND POSTER SESSION

11 :10 am

11 :50 am

SYMPOSIUM 5: Advancing the Science of Recruitment for Preclinical Alzheimer's Disease Clinical Trials

Chair: Paul Aisen, USC-ATRI, San Diego (United States)

Presentation 1: Impact of upcoming FDA enrollment requirements on recruitment for Alzheimer's disease clinical trials

Lowell Schiller, Schaeffer Institute for Public Policy & Government Service – Washington, DC (United States)

Presentation 2: Recruitment and screening in TRAILBLAZER-ALZ 3: A decentralized study of donanemab in preclinical Alzheimer's disease

Karen C. Holdridge, Eli Lilly & Company – Indianapolis (United States)

Presentation 3: Building a scalable and efficient recruitment funnel for preclinical Alzheimer's disease: The AHEAD 3-45 model

Rema Raman, USC-ATRI, San Diego (United States)

11 :50 am

12 :35 pm

ORAL COMMUNICATIONS

OC30: Interim analysis of post-marketing observational study of lecanemab in Japan

Iwata Atsushi¹, Sakata Yukinori², Koizumi Kinuyo², Endo Akira², Kuang Weijie², Sumitomo Kenta², Ishii Mika²

¹Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan), ²Eisai Co., Ltd. - Tokyo (Japan)

OC31: Completion of a Phase 2 trial evaluating safety and efficacy of the synaptic regenerative small molecule SPG302 in participants with mild-to-moderate Alzheimer's disease

Bruce Brew¹, Lauren Priest², Aimee Cazyer², Valerie Bramah³, Peter Vanderklish⁴, Craig Erickson⁴, Sharron Gargosky⁴, Stella Saraff⁴

¹St Vincent's Hospital Sydney - Darlinghurst Nsw (Australia), ²Flinders Medical Centre - Bedford Park Sa (Australia), ³Flinders Medical Centre - Darlinghurst Nsw (Australia),

⁴Spinogenix - Los Angeles (Australia)

OC32: Breaking barriers in early Alzheimer's disease diagnosis: The power of the *in vitro* diagnostic Elecsys pT181p immunoassay in a population reflective of real-world clinical practice

Sayuri Hortsch¹, David Caley², Patrick Menzel¹, Christopher Rowe³, Mark Rapp⁴, Dag Aarlsand⁵, Anna D Burke⁶, Clara Quijano-Rubio⁷

¹Roche Diagnostics GmbH - Penzburg (Germany), ²Roche Diagnostics Limited - Burgess Hill (United Kingdom), ³Australian Dementia Network Ltd - Melbourne (Australia), ⁴Berman Clinical - New York (United States), ⁵Kings College Hospital - London (United Kingdom),

⁶Barrow Neurological Institute - Phoenix (United States), ⁷Roche Diagnostics International Ltd - Rotkreuz (Switzerland)

12:35 pm
1:20 pm

LUNCH ON YOUR OWN

1:20 pm
1:35 pm

COFFEE BREAK IN THE POSTER HALL

1 :35 pm
2 :35 pm

LATE BREAKING COMMUNICATIONS

2 :35 pm
3 :50 pm

ORAL COMMUNICATIONS

OC33: The MultiTEP-based vaccine, AV-1959R, safely elicits high concentrations of antibodies specific to Aβ42 protofibrils/fibrils/plaques in vaccinated healthy volunteers.

Michael Agadjanyan¹, Lon Schneider², Alex Grinberg³, Anahit Ghochikyan⁴

¹Nuravax, Inc./Institute for Molecular Medicine - Irvine (United States), ²USC Keck School of Medicine - Los Angeles (United States), ³Arvax, Inc. - Adelaide (Australia), ⁴Institute for Molecular Medicine/Nuravax, Inc. - Huntington Beach (United States)

OC34: Clinical Performance of the Elecsys CSF pTau181/Aβ42 Ratio for Concordance with Tau-PET in Two Independent Cohorts

Ruben Smith¹, Leslie Shaw², Sebastian Palmqvist¹, Niklas Mattsson-Carlgren¹, Gregory Klein³, Matteo Tonietto³, Clara Quijano-Rubio⁴, Christopher M. Rank⁵, Myrto Andreadou⁴, Samantha C. Burnham⁶, Erik Stomrud¹

¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden Memory Clinic, Skåne University Hospital, Malmö, Sweden - Lund, Malmö

(Sweden), ²Department of Pathology and Laboratory Medicine and the PENN Alzheimer's Disease Research Center, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, PA, USA - Philadelphia (United States), ³Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland - Basel (Switzerland), ⁴Roche Diagnostics International Ltd, Rotkreuz, Switzerland - Rotkreuz (Switzerland), ⁵Roche Diagnostics GmbH, Penzberg, Germany - Penzberg (Germany), ⁶Eli Lilly and Company, Indianapolis, IN, USA - Indianapolis (United States)

OC35: Biomarkers of Cognitive Performance in Alzheimer's Disease in Adults with Down Syndrome

Jason Russell¹, Zinayida Schlachetzki¹, Alexander Conley², Brian Boyd², Paul Newhouse², Michael Rafii¹

¹Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), ²Center for Cognitive Medicine, Vanderbilt University Medical Center - Nashville (United States)

OC36: The associations between cognitive deficits and the location of tau tangles and their consistency across clinical and observational datasets

Xingjian Zhang¹, Ritobrato Datta¹, Maggie Fedgchin², Jennifer Bogert³, Janice Wong⁴, David Henley², Gayle Wittenberg², Ziad S. Saad¹

¹Johnson & Johnson, CA - San Diego (United States), ²Johnson & Johnson, NJ - Titusville (United States), ³Johnson & Johnson, NJ - Raritan (United States), ⁴Johnson & Johnson, MA - Cambridge (United States)

OC37: Strategies for Increased Representation in Trials from The NIA Health and Aging Brain Study

Charisse Winston, University of Southern California - San Diego (United States)

3:50 pm

4:20 pm

4:20 pm

5:35 pm

COFFEE BREAK AND POSTER SESSION

ORAL COMMUNICATIONS

OC38: Estimated budget impact of a screening and treatment program for preclinical Alzheimer's disease in the U.S. over 15 years

Soeren Mattke¹, Jiahe Chen¹, Eric Reiman²

¹University of Southern California - Los Angeles (United States), ²Banner Alzheimer's Institute - Phoenix (United States)

OC39: Long-Term Nicotine Treatment of Mild Cognitive Impairment: The MIND Trial

Paul Newhouse¹, Rema Raman², Brenda Armenta², Michael C Donohue², Michael S Rafii², Robert A Rissman², Edward Levin³, Kenneth Kellar⁴, Andrew Saykin⁵, Julie Dumas⁶, Patricia Andrews¹, Rachel Tyndale⁷, Brian Boyd¹, Paul Aisen²

¹Vanderbilt University Medical Center - Nashville (United States), ²University of Southern California - San Diego (United States), ³Duke University - Durham (United States), ⁴Georgetown University - Washington, Dc (United States), ⁵Indiana University - Indianapolis (United States), ⁶University of Vermont - Burlington (United States), ⁷University of Toronto - Toronto (Canada)

OC40: Impact of Nutrition, Sleep and Physical Activity on Preservation of Intellectual Function in Older Frailty Adults (INSPIOR): A Randomized Controlled Trial

Sakurai Keisuke¹, Izumi Shiraishi¹, Ryo Tanaka¹, Miwa Watanabe¹, Momoko Funakawa¹, Saori Shimada¹, Tomoko Kawaura¹, Toshiyuki Nomura², Fuka Aoki³, Takashi Matsumoto³, Yukihiro Sugawara³, Hiroki Kayama⁴, Joseph Ledsam⁴, Shin'ichi Warisawa¹, Tatsuhiro Hisatsune¹

¹The University of Tokyo - Kashiwa (Japan), ²Mitsui Fudosan, Co., Ltd. - Kashiwa (Japan),

³NH Foods Ltd. - Tsukuba (Japan), ⁴Google - Tokyo (Japan)

OC41: Mapping the Pathogenesis of Alzheimer's Disease in Down Syndrome: Imaging, Fluid Biomarkers, Cognition, and Sex Differences for Clinical Trial Design

Nazek Queder¹, Iris Chiang¹, Andrew Luu¹, Elizabeth Andrews¹, David Keator², Jenna N. Adams³, Lisa Taylor³, Michael Yassa³, Craig Stark³, Mark Mapstone⁴, Elizabeth Head¹

¹Department of Pathology & Laboratory Medicine, University of California, Irvine - Irvine (United States), ²Department of Psychiatry and Human Behavior, University of California, Irvine - Irvine (United States), ³University of California, Irvine - Irvine (United States),

⁴Department of Neurology, University of California, Irvine - Irvine (United States)

OC42: Considerations for Phase 2 Trials of an A β Vaccine, AV-1959R, for Secondary Prevention of Alzheimer's Disease

Lon Schneider¹, Michael Agadjanyan², Anahit Ghochikyan²

¹Keck School of Medicine of USC - Los Angeles (United States), ²Institute for Molecular Medicine - Huntington Beach (United States)

OC43: Tau positron emission tomography harmonization using the CenTauR approach: general conversion equations and external validation

Alexis Moscospo^{1,2}, Antoine Leuzy^{1,3}, Lau Raket Lars⁴, Victor L Villemagne^{5,6}, Gregory Klein⁷, Matteo Tonietto⁷, Emily Olafson⁸, Ruben Smith^{9,10}, Fang Xie¹¹, Hartmuth Kolb³, Nadine Tatton¹, Yashmin Karten¹, Christopher C Rowe^{12,13}, Oskar Hansson^{9,10}, Vincent Doré^{12,14}

¹Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute - Tucson (United States), ²Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n - Santiago De Compostela (Spain), ³Enigma Biomedical Group - Knoxville (United States), ⁴Eli Lilly and Company - Indianapolis (United States), ⁵Department of Psychiatry, University of Pittsburgh School of Medicine - Pittsburgh (United States), ⁶Department of Molecular Imaging & Therapy, Austin Health - Victoria (Australia), ⁷F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁸Clinical Imaging Group, Genentech, Inc. - , South San Francisco (United States), ⁹Clinical Memory Research Unit, Department of Clinical Sciences, Lund University - Lund (Sweden), ¹⁰Memory Clinic, Skåne University Hospital - Malmö (Sweden), ¹¹Department of Nuclear Medicine & PET Center, Huashan Hospital, University - Shanghai (China), ¹²Florey Department of Neuroscience, University of Melbourne - Victoria (Australia), ¹³The Australian Dementia Network (ADNeT), The University of Melbourne - Victoria (Australia), ¹⁴Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO - Victoria (Australia)